Valuation: Sanofi

Market Cap 86.01B 97.79B 81.33B 73.77B 139B 9,387B 139B 974B 376B 4,790B 367B 359B 15,393B P/E 2026 *
11.4x
P/E 2027 * 9.96x
Enterprise Value 97.47B 111B 92.17B 83.6B 157B 10,638B 158B 1,104B 426B 5,429B 416B 407B 17,445B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.86x
Free-Float
88.34%
Yield 2026 *
5.93%
Yield 2027 * 6.26%
1 day-3.36%
3 months+2.69%
6 months-5.52%
Current year-12.94%
Current year 72.95
Extreme 72.95
81.5
1 year 72.95
Extreme 72.95
86.25
3 years 72.95
Extreme 72.95
108.2
5 years 72.95
Extreme 72.95
108.2
10 years 72.95
Extreme 72.95
108.2
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer - 2026-08-31
Director TitleAgeSince
Director/Board Member 61 2019-04-29
Director/Board Member 56 2020-04-27
Director/Board Member 65 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-3.36%0.00% - - 98.02B
+0.11%+1.71%+63.08%+117.61% 1,055B
+0.27%+0.92%+49.74%+73.35% 654B
+0.73%+0.68%+19.32%+74.90% 467B
-1.36%-0.39%+40.20%+41.03% 348B
+1.34%+5.47%+23.37%+31.30% 275B
-0.48%-0.06%+13.56%+12.36% 258B
+0.85%+6.35%+52.62%+54.39% 224B
+0.85%+1.10%+35.15%+101.82% 187B
-0.30%-10.41%-27.62%-61.04% 171B
Average -0.05%+0.74%+29.94%+49.52% 404.26B
Weighted average by Cap. +0.17%+1.32%+40.03%+69.79%

Financials

2026 *2027 *
Net sales 47.65B 54.18B 45.06B 40.87B 76.75B 5,201B 77.2B 539B 208B 2,654B 203B 199B 8,528B 50.64B 57.58B 47.89B 43.44B 81.58B 5,527B 82.05B 573B 221B 2,821B 216B 212B 9,064B
Net income 7.48B 8.5B 7.07B 6.41B 12.05B 816B 12.12B 84.67B 32.7B 417B 31.92B 31.23B 1,338B 8.89B 10.1B 8.4B 7.62B 14.31B 970B 14.4B 101B 38.86B 495B 37.93B 37.11B 1,590B
Net Debt 11.46B 13.03B 10.84B 9.83B 18.46B 1,251B 18.57B 130B 50.13B 638B 48.93B 47.87B 2,052B 8.34B 9.48B 7.88B 7.15B 13.43B 910B 13.51B 94.38B 36.45B 464B 35.58B 34.81B 1,492B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
71.79EUR
Average target price
94.06EUR
Spread / Average Target
+31.02%

Quarterly revenue - Rate of surprise